← Eichor
Study identifier: NCT06383247 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease

Condition: Parkinson Disease · Transcranial Magenetic Stimualtion · Supplementary Motor Area  ·  Sponsor: Anhui Medical University

PhaseNA
Planned participants290
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.

This description comes directly from the study's public registry record.

Talk to the study team

Panpan Hu, M.D.  ·  +8613515602285  ·  hpppanda9@126.com

Kai Wang, Ph.D.  ·  +8655162923704  ·  wangkai1964@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cognitive Neuropsychology Lab Anhui Medical UniversityHefei, Anhui, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06383247